Pharm
Sofosbuvir Velpatasvir
search
Sofosbuvir Velpatasvir
, Velpatasvir/Sofosbuvir, Epclusa
See Also
Hepatitis C Antiviral Regimen
Hepatitis C
Precautions
See
Hepatitis C Antiviral Regimen
Indications
See
Hepatitis C Antiviral Regimen
Gene
ral
Initial therapy for any
Genotype
Salvage therapy with addition of Voxilaprevir as
Vosevi
(
Velpatasvir/Voxilaprevir/Sofosbuvir
)
May be used in any class of compensated
Cirrhosis
(
Child-Pugh Class
A to C
Cirrhosis
)
Ribavirin
is added to regimen in
Child-Pugh Class
C
Cirrhosis
Genotype
s
Hepatitis C
Genotype
1a
Hepatitis C
Genotype
1b
Hepatitis C
Genotype
2
Hepatitis C
Genotype
3
Hepatitis C
Genotype
4
Hepatitis C
Genotype
5 or 6
Contraindications
See
Hepatitis C Antiviral Regimen
Approved for any eGFR and for those on
Hemodialysis
Genotype
3 with
Protein
5A resistance associated Y93H substitution
Associated with
Antiviral
resistance
Mechanism
Sofosbuvir
is a NS5B Polymerase Inhibitor (...buvirs)
Velpatasvir is a NS5A
Protein
Inhibitor (...asvirs)
Dosing
Take once daily for 12 weeks
Evaluation
See
Hepatitis C Antiviral Regimen
for Pre and post-treatment protocols
Adverse Effects
See
Hepatitis C Antiviral Regimen
Headache
Fatigue
Drug Interactions
See
Hepatitis C Antiviral Regimen
Sofosbuvir
(
Sovaldi
)
Drug Interaction
s
See
Sofosbuvir
Avoid potent
P-Glycoprotein Inducer
s (reduce
Sofosbuvir
efficacy)
Avoid
Amiodarone
(severe
Bradycardia
risk)
Rosuvastatin
(
Crestor
)
Limit
Rosuvastatin
to 10 mg orally daily
Topetecan
Avoid with Epclusa
Digoxin
Epclusa may increase
Digoxin
Levels
Antacid
s (reduce Epclusa absorption)
Aluminum and Magnesium Salt Antacid
or
Calcium Carbonate
Avoid
Antacid
s if possible
Do not take
Antacid
s within 4 hours of
Harvoni
dose
H2 Blocker
s
May take at the same time as
Harvoni
, or separated by at least 12 hours
Do not use equivalent greater than
Famotidine
40 mg orally twice daily
Proton Pump Inhibitor
s
Avoid if possible
Take with food 4 hours prior to Epclusa
Do not use equivalent greater than
Omeprazole
20 mg orally daily
Monitoring
See
Hepatitis C Antiviral Regimen
Efficacy
Hepatitis C
clearance rate of >95% against all
Genotype
s
Resources
Epclusa (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f30631a-ee3b-4cfe-866b-964df3f0a44f
References
(2023) Presc Lett,
Hepatitis C
Treatment Overview, Resource #390902
(2016) Presc Lett 23(9)
Type your search phrase here